X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The company intends to use the net proceeds for its pipeline development including, IGM-8444, an IgM antibody targeting Death Receptor 5 (DR5) that is being developed for the treatment of patients with solid and hematologic malignancies.
Lead Product(s): IGM-8444,Bevacizumab,Fluorouracil
Therapeutic Area: Oncology Product Name: IGM-8444
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: BofA Securities
Deal Size: $80.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering June 22, 2023
Details:
IGM-8444 is an IgM antibody targeting death receptor 5 (DR5) that is being developed for the treatment of patients with solid tumor including metastatic colorectal cancerand hematologic malignancies.
Lead Product(s): IGM-8444,Bevacizumab,Fluorouracil
Therapeutic Area: Oncology Product Name: IGM-8444
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 02, 2023
Details:
IGM-2323 (imvotamab), a novel IgM-based CD20 x CD3 bispecific antibody T cell engager (TCE), cleared two IND applications, enabling the initiation of Phase 1b studies in both severe systemic lupus erythematosus (SLE) and severe rheumatoid arthritis (RA).
Lead Product(s): Imvotamab
Therapeutic Area: Immunology Product Name: IGM-2323
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 31, 2023
Details:
IGM-7354 is a targeted IL-15/IL-15R IgM immune stimulating antibody for the treatment of patients with solid tumors and hematologic malignancies. IGM-7354 may enhance the immune system’s activity in the tumor microenvironment.
Lead Product(s): IGM-7354
Therapeutic Area: Oncology Product Name: IGM-7354
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 17, 2023
Details:
IGM-8444 is an IgM antibody targeting Death Receptor 5 (DR5) that is being developed for the treatment of patients with solid and hematologic malignancies.
Lead Product(s): IGM-8444,Bevacizumab,Fluorouracil
Therapeutic Area: Oncology Product Name: IGM-8444
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 09, 2023
Details:
Imvotamab (IGM-2323), the first-in-class CD20xCD3 bispecific IgM antibody with dual mechanisms of action, in patients with advanced B cell malignancies.
Lead Product(s): Imvotamab
Therapeutic Area: Oncology Product Name: IGM-2323
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 11, 2022
Details:
The collaboration is for the creation, development, manufacture, and commercialization of IgM antibody agonists against three oncology targets and three immunology/inflammation targets.
Lead Product(s): Engineered IgM Antibody
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Large molecule
Partner/Sponsor/Collaborator: Sanofi
Deal Size: $6,150.0 million Upfront Cash: $150.0 million
Deal Type: Collaboration May 06, 2022
Details:
Under collaboration Sanofi and IGM will lead research, develop and commercialize IgM antibody agonists against three oncology targets and three immunology/inflammation targets by leveraging proprietary IgM antibody technology platform.
Lead Product(s): Engineered IgM Antibody
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Large molecule
Partner/Sponsor/Collaborator: Sanofi
Deal Size: $6,165.0 million Upfront Cash: $150.0 million
Deal Type: Collaboration March 29, 2022
Details:
Based on the results, two Phase 2 studies are being initiated to assess the safety and efficacy of two doses of IGM-2323, in patients with DLBCL and FL. Data demonstrate that IGM-2323 is highly active against multiple subtypes of relapsed/ refractory non-Hodgkin’s lymphoma.
Lead Product(s): IGM-2323
Therapeutic Area: Oncology Product Name: IGM-2323
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 11, 2021
Details:
Studies suggest that anti-CSP (circumsporozoite protein) monoclonal antibodies may be useful in protecting against infection and disease. Because of their multimeric format, IgM and IgA antibodies directed against CSP could potentially exhibit significantly improved potency.
Lead Product(s): Anti-CSP IgM Antibodies
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Bill & Melinda Gates Foundation
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration December 08, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
